Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:
“ctDNA gives a good indicator of MRD post surgery in MIBC and is predictive of response to atezo. It is also prognostic in most MIBC settings.
Less is known about utDNA. In SUNRISE4 the utDNA results are novel and show utDNA clearance, which may correlate with pCR. Integrated utDNA and ctDNA analysis will help guide treatment IMO.”
More posts featuring Thomas Powles on OncoDaily.
